Breaking World Pharma News

Drug combo suppresses growth of late-stage prostate cancer tumors

Low doses of metformin, a widely used diabetes medication, and a gene inhibitor known as BI2536 can successfully halt the growth of late-stage prostate cancer tumors, a Purdue University study finds. Prostate cancer causes the second-highest number of cancer-related deaths in men in the U.S., and methods of treating advanced prostate cancer are limited.

Read more...

Bristol-Myers Squibb reports fourth quarter and full year 2014 financial results

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2014, which were highlighted by strong global sales for priority brands and important advances in the company's immuno-oncology (I-O) portfolio.

Read more...

New 'systems genetics' study identifies possible target for epilepsy treatment

A single gene that coordinates a network of about 400 genes involved in epilepsy could be a target for new treatments, according to research. Epilepsy is a common and serious disease that affects around 50 million people worldwide. The mortality rate among people with epilepsy is two to three times higher than the general population.

Read more...

Major milestone for GSK/NIH candidate Ebola vaccine as first doses shipped to Liberia for use in phase III clinical trial

GlaxoSmithKlineGSK has announced that the first batch of its candidate Ebola vaccine is being shipped to west Africa and is expected to arrive in Liberia later today Friday 23 January. The shipment, containing an initial 300 vials of the candidate vaccine, is the first to arrive in one of the main Ebola affected countries and will be used to start the first large-scale efficacy trial of experimental Ebola vaccines in the coming weeks.

Read more...

Long-term use of hormonal contraceptives is associated with an increased risk of brain tumors

Taking a hormonal contraceptive for at least five years is associated with a possible increase in a young woman's risk of developing a rare tumour, glioma of the brain. This project focussed on women aged 15-49 years and the findings are published in the British Journal of Clinical Pharmacology.

Read more...

Roche acquires Trophos to expand portfolio in neuromuscular disease with high medical need

RocheRoche (SIX: RO, ROG; OTCQX: RHHBY) has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos's proprietary screening platform generated olesoxime (TRO19622), which is being developed for SMA - a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children.

Read more...

Drinking moderate amounts of alcohol is linked to reduced risk of heart failure

Evidence already exists for the beneficial effects of drinking moderate amounts of alcohol on the risk of developing a number of heart conditions; however, the role it plays in the risk of developing heart failure has been under-researched with conflicting results. Now, a large study of nearly 15,000 men and women, published online in the European Heart Journal, shows that

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]